Significance of a tetracycline and Pepto-Bismol interaction in the management of Helicobacter pylori-induced peptic ulcer disease.
Tkach
C L
CL
Ariano
R E
RE
D001729:Bismuth / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy*; D012459:Salicylates / Q000627:therapeutic use*; D013752:Tetracycline / Q000627:therapeutic use*
D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; D013752:Tetracycline; D001729:Bismuth